Seres Therapeutics Secures $3.6M CARB-X Award, Plans Phase 1b SER-428 Trial
Seres Therapeutics will present its live biotherapeutics platform and collaboration with CARB-X at the CARB-X Investor Day on April 16, preceding ESCMID in Munich. The company received a $3.6 million non-dilutive CARB-X award in 2025 to advance SER-428 oral liquid formulation and is designing a Phase 1b ICU trial.
1. CARB-X Investor Day Presentation
On April 16 Seres Therapeutics will showcase its live biotherapeutics platform and longstanding collaboration with CARB-X at the CARB-X Investor Day in Munich, highlighting its strategy to combat antimicrobial resistance with novel therapeutics.
2. CARB-X Non-Dilutive Award
In 2025 Seres received a second CARB-X grant totaling $3.6 million to support development of an oral liquid formulation based on SER-155 strains, now dubbed SER-428, for patients unable to swallow capsules such as those in medical ICUs.
3. SER-428 Phase 1b Trial Design
The company is designing a Phase 1b open-label trial in partnership with Dr. Dan Freedberg at Columbia University to evaluate SER-428 dosing in ICU patients at high risk of drug-resistant infections.
4. Additional Pipeline Initiatives
Seres is also advancing its broader pipeline, including Phase 2-ready SER-155 for bloodstream infections in allo-HSCT patients, SER-603 for inflammatory bowel disease, and an investigator-sponsored SER-155 trial in immune checkpoint inhibitor–related enterocolitis.